ST. LOUIS, Feb. 4, 2011 /PRNewswire/ -- K-V Pharmaceutical
Company (NYSE: KVa/KVb) (the "Company") announced today it
will host a conference call on Monday,
February 14, 2011 at 10:00 a.m.
EST to discuss the U.S. Food & Drug Administration
approval of Makena™ as well as provide a general update on other
company matters.
Participants can listen to the conference call by dialing
412-317-6789. To access the live web cast of the conference call,
please go to the investor relations portion of the Company's
website under "conference calls" at
http://www.kvpharmaceutical.com. Please log-in or dial-in at least
10 minutes prior to the start time to ensure a connection.
A replay of the call will also be available for seven days by
calling 412-317-0088 and citing code 445162. An archived version of
the webcast will be accessible for 30 days at
http://www.kvpharmaceutical.com.
About K-V Pharmaceutical Company
K-V Pharmaceutical Company is a fully-integrated specialty
pharmaceutical company that develops, manufactures, markets, and
acquires technology-distinguished branded prescription
pharmaceutical products. The company markets its
technology-distinguished products through Ther-Rx Corporation, its
branded drug subsidiary. For further information about K-V
Pharmaceutical Company, please visit the company's corporate Web
site at www.kvpharmaceutical.com.
SOURCE K-V Pharmaceutical Company